Yolande Lievens
Overview
Explore the profile of Yolande Lievens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
3305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, et al.
J Thorac Oncol
. 2025 Feb;
PMID: 39927917
No abstract available.
2.
Tsao M, Rosenthal A, Nicholson A, Detterbeck F, Eberhardt W, Lievens Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864546
Introduction: Pulmonary high-grade neuroendocrine carcinoma (NEC) includes SCLC and large cell NEC (LCNEC). The seventh and eighth editions of the TNM classification for lung cancer confirmed the applicability of this...
3.
Corral J, Algara M, Munoz-Montplet C, Eraso A, Giralt J, Defourny N, et al.
Front Public Health
. 2025 Jan;
12:1474376.
PMID: 39749236
Background And Purpose: The aim was to estimate the cost of the external beam radiotherapy (EBRT) in public health care centers in Catalonia (Spain), according to the ESTRO-HERO costing model...
4.
Aguado-Barrera M, Lopez-Pleguezuelos C, Gomez-Caamano A, Calvo-Crespo P, Taboada-Valladares B, Azria D, et al.
Lung Cancer
. 2024 Dec;
199:108072.
PMID: 39740425
Background And Purpose: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Materials And Methods: Data...
5.
Zeng H, Schagen S, Hendriks L, Sanchez-Benavides G, Jaspers J, Manero R, et al.
Lung Cancer
. 2024 Nov;
199:108036.
PMID: 39615412
Background: Cognitive decline is an arising concern in patients who need cranial irradiation. We used the pooled longitudinal individual patient data of two phase III trials: NCT01780675 and PREMER to...
6.
Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, et al.
Lancet Oncol
. 2024 Oct;
25(11):e545-e580.
PMID: 39362232
Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of...
7.
Grover S, Court L, Amoo-Mitchual S, Longo J, Rodin D, Scott A, et al.
Semin Radiat Oncol
. 2024 Sep;
34(4):477-493.
PMID: 39271284
There has long existed a substantial disparity in access to radiotherapy globally. This issue has only been exacerbated as the growing disparity of cancer incidence between high-income countries (HIC) and...
8.
Alongi F, Nicosia L, Ricardi U, Scorsetti M, Greto D, Balermpas P, et al.
Radiother Oncol
. 2024 Aug;
199:110466.
PMID: 39094630
Aim: To evaluate acute toxicity at 6 months after stereotactic body radiotherapy (SBRT) in patients with oligometastatic cancer within the OligoCare cohort. Material And Methods: OligoCare is a prospective, registry-based,...
9.
Lievens Y, Janssens S, Lambrecht M, Engels H, Geets X, Jansen N, et al.
Lancet Reg Health Eur
. 2024 Jul;
44:100992.
PMID: 39045286
Background: Although stereotactic body radiotherapy (SBRT) was progressively adopted in clinical practice in Belgium, a reimbursement request in 2011 was not granted because of remaining clinical and economic uncertainty. A ...
10.
Khan Y, Verhaeghe N, De Pauw R, Devleesschauwer B, Gadeyne S, Gorasso V, et al.
PLoS One
. 2024 Jun;
19(6):e0306495.
PMID: 38935602
[This corrects the article DOI: 10.1371/journal.pone.0288777.].